ArticleJournal of clinical medicine2024

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

Oğuzcan Kınıkoğlu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.